Increased studies have shown that CRMP-2 could be used as a target for the treatment of various neurological disorders including Alzheimer’s disease (Cheung and Ip, 2012) and spinal cord neurons degeneration (Petratos et al., 2012). This evidence concerns the gene DPYSL2 and Alzheimer disease.